遗传性经甲状腺素淀粉样变性患者临床评估的新见解:单一中心的经验。

Ole B Suhr, Sandra Gustavsson, Victoria Heldestad, Rolf Hörnsten, Per Lindqvist, Erik Nordh, Urban Wiklund
{"title":"遗传性经甲状腺素淀粉样变性患者临床评估的新见解:单一中心的经验。","authors":"Ole B Suhr,&nbsp;Sandra Gustavsson,&nbsp;Victoria Heldestad,&nbsp;Rolf Hörnsten,&nbsp;Per Lindqvist,&nbsp;Erik Nordh,&nbsp;Urban Wiklund","doi":"10.2147/DNND.S24652","DOIUrl":null,"url":null,"abstract":"<p><p>Over the last decade, new medical treatment modalities have emerged based on increased insights into amyloid formation. With the increased possibilities for treatment of amyloidosis caused by transthyretin (TTR) amyloid deposits comes the need for diagnostic procedures for early diagnosis and better tools to follow disease progression. This is of particular importance in clinical trials evaluating the efficacy of new treatments. Until recently, the treatment of TTR amyloidosis (ATTR) was based solely on liver transplantation, a procedure that has halted disease progression in many patients. Liver transplantation has been especially effective in patients under the age of 50 years carrying the TTR V30M mutation, whereas the outcome of the procedure has been variable for others, particularly elderly male patients and those carrying a non-V30M mutation. This review concentrates on new insights derived from our center's experience with liver transplantation, how to implement this experience in evaluation of new treatment modalities for ATTR, and how to facilitate early diagnosis of neuropathy with easily available diagnostic tools. Attention has focused on manifestations of the disease that involve the heart and the peripheral nervous system; change in peripheral nerve function has been the primary endpoint in two controlled clinical trials, one finished and one ongoing. New insights into the amyloid formation process and the lessons learned from liver transplantation give the opportunity to design potentially effective treatment modalities for ATTR. It appears reasonable to suspect that a combination of different treatment modalities may be required to treat the disease, and that different treatment regimes will be designed according to the phenotype of the disease. For the patients and their relatives there is now a solid foundation for optimism, with prospects of several effective medical treatment possibilities within the coming decade.</p>","PeriodicalId":11147,"journal":{"name":"Degenerative Neurological and Neuromuscular Disease","volume":"2 ","pages":"93-106"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/DNND.S24652","citationCount":"5","resultStr":"{\"title\":\"New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience.\",\"authors\":\"Ole B Suhr,&nbsp;Sandra Gustavsson,&nbsp;Victoria Heldestad,&nbsp;Rolf Hörnsten,&nbsp;Per Lindqvist,&nbsp;Erik Nordh,&nbsp;Urban Wiklund\",\"doi\":\"10.2147/DNND.S24652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Over the last decade, new medical treatment modalities have emerged based on increased insights into amyloid formation. With the increased possibilities for treatment of amyloidosis caused by transthyretin (TTR) amyloid deposits comes the need for diagnostic procedures for early diagnosis and better tools to follow disease progression. This is of particular importance in clinical trials evaluating the efficacy of new treatments. Until recently, the treatment of TTR amyloidosis (ATTR) was based solely on liver transplantation, a procedure that has halted disease progression in many patients. Liver transplantation has been especially effective in patients under the age of 50 years carrying the TTR V30M mutation, whereas the outcome of the procedure has been variable for others, particularly elderly male patients and those carrying a non-V30M mutation. This review concentrates on new insights derived from our center's experience with liver transplantation, how to implement this experience in evaluation of new treatment modalities for ATTR, and how to facilitate early diagnosis of neuropathy with easily available diagnostic tools. Attention has focused on manifestations of the disease that involve the heart and the peripheral nervous system; change in peripheral nerve function has been the primary endpoint in two controlled clinical trials, one finished and one ongoing. New insights into the amyloid formation process and the lessons learned from liver transplantation give the opportunity to design potentially effective treatment modalities for ATTR. It appears reasonable to suspect that a combination of different treatment modalities may be required to treat the disease, and that different treatment regimes will be designed according to the phenotype of the disease. For the patients and their relatives there is now a solid foundation for optimism, with prospects of several effective medical treatment possibilities within the coming decade.</p>\",\"PeriodicalId\":11147,\"journal\":{\"name\":\"Degenerative Neurological and Neuromuscular Disease\",\"volume\":\"2 \",\"pages\":\"93-106\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/DNND.S24652\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Degenerative Neurological and Neuromuscular Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/DNND.S24652\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Degenerative Neurological and Neuromuscular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/DNND.S24652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

在过去的十年里,基于对淀粉样蛋白形成的深入了解,出现了新的医疗模式。随着治疗由转甲状腺素(TTR)淀粉样蛋白沉积引起的淀粉样变性的可能性增加,需要早期诊断的诊断程序和更好的工具来跟踪疾病进展。这在评估新疗法疗效的临床试验中尤为重要。直到最近,TTR淀粉样变性(ATTR)的治疗还完全基于肝移植,这一手术已经阻止了许多患者的疾病进展。肝移植对携带TTR V30M突变的50岁以下患者尤其有效,而对其他患者,尤其是老年男性患者和携带非V30M基因突变的患者,肝移植的结果是可变的。这篇综述集中于从我们中心的肝移植经验中获得的新见解,如何在评估ATTR的新治疗模式中实施这一经验,以及如何使用易于获得的诊断工具促进神经病变的早期诊断。人们的注意力集中在涉及心脏和外周神经系统的疾病表现上;外周神经功能的改变是两项对照临床试验的主要终点,一项已完成,另一项正在进行。对淀粉样蛋白形成过程的新见解和从肝移植中吸取的教训为设计潜在有效的ATTR治疗模式提供了机会。似乎有理由怀疑,治疗该疾病可能需要不同治疗模式的组合,并且将根据疾病的表型设计不同的治疗方案。对于患者及其亲属来说,现在有了坚实的乐观基础,在未来十年内有可能获得几种有效的医疗治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
New insights into the clinical evaluation of hereditary transthyretin amyloidosis patients: a single center's experience.

Over the last decade, new medical treatment modalities have emerged based on increased insights into amyloid formation. With the increased possibilities for treatment of amyloidosis caused by transthyretin (TTR) amyloid deposits comes the need for diagnostic procedures for early diagnosis and better tools to follow disease progression. This is of particular importance in clinical trials evaluating the efficacy of new treatments. Until recently, the treatment of TTR amyloidosis (ATTR) was based solely on liver transplantation, a procedure that has halted disease progression in many patients. Liver transplantation has been especially effective in patients under the age of 50 years carrying the TTR V30M mutation, whereas the outcome of the procedure has been variable for others, particularly elderly male patients and those carrying a non-V30M mutation. This review concentrates on new insights derived from our center's experience with liver transplantation, how to implement this experience in evaluation of new treatment modalities for ATTR, and how to facilitate early diagnosis of neuropathy with easily available diagnostic tools. Attention has focused on manifestations of the disease that involve the heart and the peripheral nervous system; change in peripheral nerve function has been the primary endpoint in two controlled clinical trials, one finished and one ongoing. New insights into the amyloid formation process and the lessons learned from liver transplantation give the opportunity to design potentially effective treatment modalities for ATTR. It appears reasonable to suspect that a combination of different treatment modalities may be required to treat the disease, and that different treatment regimes will be designed according to the phenotype of the disease. For the patients and their relatives there is now a solid foundation for optimism, with prospects of several effective medical treatment possibilities within the coming decade.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信